Medication info

CG-Pra 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injectionApproval withdrawn
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Huons Life Science Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets / PTP [14 tablets / Alu-Alu x 2]
Approval status
Approval withdrawn

MFDS item code 202002255 · Approved 2020.03.31

This product's status changed to Approval withdrawn on 2024.04.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment and prevention of acid-related disorders, ulcers (including eradication therapy and rebleeding), and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance treatment to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continued nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience in patients with severe renal failure. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly patients: No dosage adjustment is necessary.
Children's dosage
Adolescents aged 12 years or older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. Pediatric patients under 12 years of age: There is no experience with administration of this drug to pediatric patients under 12 years of age.

Ingredients

Manufacturer
Huons Life Science Co., Ltd.

Efficacy & effects

Treatment and prevention of acid-related disorders, ulcers (including eradication therapy and rebleeding), and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • symptoms of gastroesophageal reflux disease without esophagitis
  • Helicobacter pylori-positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • NSAID-related gastric ulcers
  • NSAID-related duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is effective for the treatment and symptom relief of gastroesophageal reflux disease and erosive reflux esophagitis. It is also used in combination with antibiotics for the eradication of Helicobacter pylori and for the treatment and prevention of recurrence in patients with duodenal ulcers and peptic ulcers. It assists in the treatment of gastrointestinal symptoms associated with NSAIDs and in the treatment and prevention of gastric ulcers and duodenal ulcers. It contributes to patient health improvement by treating Zollinger-Ellison syndrome and providing maintenance therapy to prevent rebleeding. Therefore, it is widely used for the treatment of various gastrointestinal diseases and symptoms.

Dosage and Administration

Adult dosage

1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance treatment to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric or duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continued nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience in patients with severe renal failure. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. Elderly patients: No dosage adjustment is necessary.

Children's dosage

Adolescents aged 12 years or older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. Pediatric patients under 12 years of age: There is no experience with administration of this drug to pediatric patients under 12 years of age.

Precautions

This medication should not be administered to certain patients. For example, patients allergic to this medication or its ingredients or those who have experienced hypersensitivity should not take it. In addition, patients allergic to penicillin or macrolide antibiotics should exercise caution if taking this medication in combination. Concurrent use with certain heart-related medications or antiviral agents is prohibited. This medication is not recommended for nursing mothers. During treatment, although rare, blood disorders such as leukopenia, thrombocytopenia, hypomagnesemia, hypersensitivity reactions, gastrointestinal symptoms, skin rashes, and various side effects may occur; if any abnormal symptoms arise, consult a doctor immediately. Regular check-ups are needed with long-term use, especially after over a year of continuous use, magnesium levels should be checked periodically. As this medication inhibits gastric acid secretion, there is a slight increased risk of bacterial infections in the gastrointestinal tract, and the risk of fractures may also increase, thus caution is needed for patients at risk of osteoporosis. This medication has many drug interactions, so it is essential to consult healthcare personnel regarding the concurrent use of other medications during treatment with this drug. Although no significant issues were found in animal studies during pregnancy, it should be prescribed cautiously to pregnant women, and breastfeeding mothers should avoid taking it. There is no specific antidote for overdose, so appropriate treatment according to symptoms should be administered, and it should be kept out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucinations, headache, dizziness, sensory disturbances, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized pustular psoriasis, eosinophilia with systemic symptoms drug reaction, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid tumor, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stool, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, ear pain, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatic polymyalgia, anorexia, apathy, increased appetite, confusion, worsening depression, muscle hypertonicity, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disturbances, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered olfaction, taste loss, taste distortion, urination abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic gland polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or humidity from entering. Additionally, it should be kept at room temperature between 1°C to 30°C, avoiding very cold or hot places.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets / PTP [14 tablets / Alu-Alu x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.